EDX Medical (EDX) is a precision diagnostics company developing next-generation cancer and disease tests designed to deliver ultra-high accuracy, earlier detection and more personalised healthcare outcomes. Following its recent move from the Aquis Exchange to AIM, the company is entering a significant new phase of commercialisation, institutional visibility and international growth.
In this interview, Founder and Chief Scientific Officer Professor Chris Evans discusses EDX Medical’s ambition to become a leading player in precision diagnostics, the commercial rollout of its breakthrough cancer testing platforms, and how advances in AI, genomics and preventative healthcare are transforming modern medicine.
In this interview, investors will hear:
• Why EDX Medical believes accuracy and clinical usability are the key differentiators in precision diagnostics
• How the move to AIM is expected to improve institutional visibility, liquidity and support future commercial expansion
• The commercial rollout plans for its testicular, bowel and prostate cancer diagnostics platforms
• How AI, genomics and molecular diagnostics are shaping the future of personalised medicine and preventative healthcare
Professor Chris Evans, Founder & Chief Scientific Officer of EDX Medical, was interviewed by John Hughman for Focus IR.
